CA3057768A1 - Prevention and treatment of non-melanoma skin cancer (nmsc) - Google Patents

Prevention and treatment of non-melanoma skin cancer (nmsc) Download PDF

Info

Publication number
CA3057768A1
CA3057768A1 CA3057768A CA3057768A CA3057768A1 CA 3057768 A1 CA3057768 A1 CA 3057768A1 CA 3057768 A CA3057768 A CA 3057768A CA 3057768 A CA3057768 A CA 3057768A CA 3057768 A1 CA3057768 A1 CA 3057768A1
Authority
CA
Canada
Prior art keywords
mrna
ifn
alpha
utr
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3057768A
Other languages
English (en)
French (fr)
Inventor
Markus Mandler
Achim Schneeberger
Walter Schmidt
Frank Mattner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accanis Biotech F&e & Co KG GmbH
Original Assignee
Accanis Biotech F&e & Co KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accanis Biotech F&e & Co KG GmbH filed Critical Accanis Biotech F&e & Co KG GmbH
Publication of CA3057768A1 publication Critical patent/CA3057768A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
CA3057768A 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc) Pending CA3057768A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17164257 2017-03-31
EP17164257.2 2017-03-31
EP17200162 2017-11-06
EP17200162.0 2017-11-06
PCT/EP2018/058036 WO2018178215A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Publications (1)

Publication Number Publication Date
CA3057768A1 true CA3057768A1 (en) 2018-10-04

Family

ID=61763994

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3057768A Pending CA3057768A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Country Status (8)

Country Link
US (1) US20200038487A1 (https=)
EP (2) EP4019037A1 (https=)
JP (1) JP7264867B2 (https=)
KR (1) KR20190133216A (https=)
CN (1) CN110636854A (https=)
AU (1) AU2018246292A1 (https=)
CA (1) CA3057768A1 (https=)
WO (1) WO2018178215A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101987591B1 (ko) * 2018-08-06 2019-06-10 국립해양생물자원관 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도
WO2020227625A1 (en) 2019-05-08 2020-11-12 Laura Hansen 14-3-3 targeting peptides for cancer treatment
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
CN115887495A (zh) * 2022-07-11 2023-04-04 上海默多赛生物科技有限公司 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
CA1295243C (en) * 1986-05-27 1992-02-04 Daniel J. Tanner Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) * 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
EP0351974A1 (en) 1988-07-05 1990-01-24 Schering Corporation Treatment of genital warts with a combination of podophyllin and recombinant DNA human alpha interferon
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
BR9712362A (pt) * 1996-10-18 1999-08-31 Canji Inc Métodos e composições para distribuição e expressão de ácidos nucléicos de alfa-interferon
CA2323604A1 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
RU2262510C9 (ru) 1999-05-19 2006-04-20 Лексиген Фармасьютикэлс Корп. Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
CA2976376A1 (en) * 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990881C (en) 2015-06-30 2024-02-20 Ethris Gmbh Utrs increasing the translation efficiency of rna molecules

Also Published As

Publication number Publication date
EP3600379A1 (en) 2020-02-05
CN110636854A (zh) 2019-12-31
AU2018246292A1 (en) 2019-10-10
EP3600379B1 (en) 2022-12-21
JP7264867B2 (ja) 2023-04-25
EP4019037A1 (en) 2022-06-29
JP2020515644A (ja) 2020-05-28
KR20190133216A (ko) 2019-12-02
WO2018178215A1 (en) 2018-10-04
US20200038487A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
EP3600379B1 (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
CN109476718B (zh) 编码免疫调节多肽的mrna的组合及其用途
KR102399799B1 (ko) 인공 핵산 분자
JP2021075578A (ja) 工学操作された核酸の送達および製剤
CN103003427B (zh) 具有佐剂活性的新型核酸及其应用
US20200369738A1 (en) Treatment of Local Skin Hypotrophy Conditions
JP2015096073A (ja) 阻害性オリゴヌクレオチドを送達するための組成物および方法
WO2011146938A1 (en) Reagents and methods for treating cancer
KR20220108031A (ko) 인공 합성 mRNA 및 그 이용
EP2682462B1 (en) (nucleic acid)-polysaccharide complex
Liu et al. Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line
JP2023088734A (ja) Ｒｎａを含有する抗腫瘍剤、免疫細胞の活性化方法、腫瘍細胞の転移の抑制方法、免疫賦活剤、抗腫瘍剤の抗腫瘍効果の増強剤、及び医薬組成物
HK40067000A (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
Trojan et al. IGF-I antisense and triple-helix gene therapy of glioblastoma
JP2006180710A (ja) Ｋｌｆ５遺伝子の発現を抑制するｒｎａ
JP2003512442A (ja) 癌の治療法
KR20250109232A (ko) 포유류에서 엘라스틴 신생합성을 유도하기 위한 코돈 최적화 올리고뉴클레오티드
WO2024190328A1 (ja) 組成物およびその利用
EP4558635A2 (en) Methods and compositions for selectively modulating gene expression in megakaryocytes and platelets
WO2024190329A1 (ja) 組成物およびその利用
Double-Stem-Loop 644. Decreased Generation and Cytotoxic Function of Adenovirus-Specific CD8 T Cells in Both CD28 and FasL Deficient Mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220831